Immunologic aspects of neurologic and neuromuscular diseases

JAMA

Volumn 278, Issue 22, 1997, Pages 1956-1961

  Smith, Derek R ^a   Weiner, Howard L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; PATHOGENESIS; POLYMYOSITIS; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW;

EID: 0031454225     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1956     Document Type: Review

References (49)

1. French L, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol. 1996;133:335-343.
2. Steinman L, Lindsey JW, Alters S, Hodgkinson S. From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis. In: Bach JF, ed. Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases. New York, NY: Marcel Dekker Inc; 1993:253-260.
3. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis using attenuated cells of a T lymphocyte line reactive against myelin basic protein. Nature. 1981;292:60-61.
4. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of TGF-b, IL-4 and PGE expression in the brain. J Exp Med. 1992;46:1355-1364.
5. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237-1240.
6. Engel A, Emslie-Smith A. Inflammatory myopathies. Curr Opin Neurol Neurosurg. 1989;2:695.
7. Kissel J, Mendell J, Rammohan K. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314: 329-334.
8. Hohlfield R, Engel A, Kunio L, Harper R. Polymyositis mediated by T lymphocytes that express gamma/delta receptors. N Engl J Med. 1991;324: 877-881.
9. Kalovidouris A, Pourmand R, Passo M, Plotkin Z. Proliferative response of PBMC to autologous and allogenic muscle in patients with PM/DM. Arthritis Rheum. 1989;32:446-443.
10. Targoff I. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am. 1994;20:857-880.
11. Miller F, Leitman S, Cronin M, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992; 326:1380-1384.
12. Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S. Altered intrathymic T cell repertoire in human myasthenia gravis. Ann Neurol. 1997;41:731-741.
13. Yi Q, Lefvert A. Idiotype and anti-idiotype reactive T lymphocytes in myasthenia gravis: evidence for the involvement of different subpopulations of T helper lymphocytes. J Immunol. 1994; 153:3353-3359.
14. Durelli I, Maggi G, Casadio C, et al. Actuarial analysis of the occurrence of remission following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychol. 1991;54:406.
15. Sela M, Kirshner S, Katz-Levy Y, et al. Dominant epitopes and synthetic peptides in myasthenia gravis. Israel J Med Sci. 1995;31:10.
16. Wang Z, Huang J, Olsson T, He B, Link H. B cell responses to AChR in rats orally tolerized against EAMG. J Neurol Sci. 1995;128:167-174.
17. Latov N. Evaluation and treatment of patients with neuropathy and monoclonal gammopathy. Semin Neurol. 1994;14:118-122.
18. Notermans NC, Lokhorst HM, Franssen II, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology. 1996;47:1227-1233.
19. Pestronk A, Lopate G, Kornberg AJ, et al. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies' improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology. 1994;44:2027-2031.
20. Ibsen S, Clausen J. A repetitive DNA sequence 5′ to the human myelin basic protein gene may be linked to MS in Danes. Acta Neurologica Scandinavica. 1996;93:236-240.
21. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1, B7-2, and IL-12 in MS lesions. J Exp Med. 1995;182:1985-1996.
22. Gerritse K, Laman J, Noelle R, et al. CD40-CD40L interactions in EAE and MS. Proc Natl Acad Sci U S A. 1996;93:2499-2504.
23. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner H, Hafler D. Increased frequency of IL-2 responsive T cells specific for MBP and PLP in peripheral blood and CSF of patients with MS. J Exp Med. 1994;179:973-984.
24. Lodge P, Johnson C, Sriram S. Frequency of MBP and MBP peptide reactive T cells in the HPRT mutant T cell population of MS patients. Neurology. 1996;46:1410-1415.
25. Kerero de Rosbo N, Milo R, Lees M, Burger D, Bernard C, Ben-Nun A. Reactivity to myelin antigens in MS: PBL respond predominantly to MOG. J Clin Invest. 1993;92:2602-2608.
26. Balashov K, Smith D, Hafler D, Khoury S, Weiner H. Increased IL-12 production in progressive MS: induction by activated CD4 T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997;94:599-603.
27. Haines J, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex: the Multiple Sclerosis Genetics Group. Nat Genet. 1996;13:469-471.
28. Paty DW, Li DKB, and IFN-B MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: MRI results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
29. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology. 1994;44:1-4.
30. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581-588.
31. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;239:1764-1769.
32. Group TIMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
33. IFN-B MS Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995; 45:1277.
34. Jacobs L. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
35. Durelli L, Bongioanni M, Ferrero B, et al. Interferon alpha treatment of relapsing remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology. 1996;47:123-129.
36. David M, Petricoin EI, Benjamin C, et al. Requirement of MAP kinase (ERK2) activity in interferon alpha and interferon beta stimulated gene expression through STAT proteins. Science. 1995;269: 1721.
37. Arnason BGW. Interferon beta in multiple sclerosis. Neurology. 1993;43:641-643.
38. Hirsch RL, Panitch HS, Johnson KP. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Invest. 1987;22:139.
39. Noronha A, Toscas A, Jensen MA. IFN-b down-regulates T cell activation and IFN-g production: implications for MS. J Neuroimmunol. 1993;46:145.
40. Smith D, Balshov K, Hafler D, Khoury S, Weiner H. Immune deviation following cyclophosphamide/ methylprednisolone treatment of multiple sclerosis: increased IL-4 and associated eosinophilia. Ann Neurol. 1997;42:313-318.
41. Rudick R. In vitro and in vivo inhibition of mitogen driven T cell activation by recombinant interferon beta. Neurology. 1993;43:2080-2087.
42. Porrini AM, Gambi D, Reder AT. Interferon effects on IL-10 secretion: mononuclear cell response to IL-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995;61:27-34.
43. Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268.
44. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993;259:1321-1324.
45. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993;43:910-918.
46. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in MS: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychol. 1997;62:112-118.
47. Goodkin D, Rudick R, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37:30.
48. Sipe JD, Romine J, Koziol J, McMillan R, Zyroff J, Beutler E. Cladribine in the treatment of chronic progressive multiple sclerosis. Lancet. 1994;344:9.
49. Furneaux H, Reich L, Posner J. Autoantibody synthesis in the CNS of patients with paraneoplastic syndromes. Neurology. 1990;7:1085-1091.